Scientific job: CLAIMED. This article owns the public persistent treatment state from kidney-replacement indication → modality choice → haemodialysis/peritoneal dialysis → vascular or peritoneal access → treatment prescription/session → fluid and solute removal → adequacy and complications → home/community handoff → repeated longitudinal treatment. Renal Medicine retains kidney disease and the decision that kidney replacement is needed; this node owns the machinery, access and recurring treatment state once dialysis becomes the intervention.

Wait, what? Dialysis is not a machine that simply “cleans the blood”.

Healthy kidneys continuously regulate water, electrolytes, acid–base balance and waste handling. Dialysis replaces only part of that work and does so intermittently or through another compartment. A person can therefore be “on dialysis” and still have problems with fluid, potassium, blood pressure, nutrition, anaemia, bone-mineral balance, access function and residual kidney function.

This is why dialysis needs its own movement node: kidney failure is the disease state; dialysis is a persistent treatment state that travels with the person across every later handoff.

The dialysis tube

Kidney replacement needed → modality decision → access established → prescription → treatment delivered → fluid/solute removal → adequacy + symptoms + access function → complications → adjustment → community/home return → repeat treatment state.

1. Modality is part of the patient state

Singapore MOH distinguishes two main community dialysis routes: haemodialysis, usually performed in a dialysis centre, and peritoneal dialysis, which can be performed at home. In April 2026, MOH reiterated a peritoneal-dialysis-preferred strategy for clinically suitable patients, while preserving clinical judgement and affordability across both modalities.

For eduKateAI, “dialysis” is therefore too coarse. The route should preserve modality, setting, schedule, access type, residual kidney function, current dry-weight/volume target where clinically relevant and responsible dialysis provider.

2. Haemodialysis and peritoneal dialysis use different compartments

Haemodialysis circulates blood through an external dialyser. Peritoneal dialysis uses the lining of the abdominal cavity as the exchange membrane. They therefore create different access, infection, lifestyle and treatment-management questions.

For eduKateAI: HD ≠ PD. A dialysis complication or care instruction must remain attached to the correct modality.

3. Access is a persistent clinical object

Haemodialysis may use an arteriovenous fistula, graft or catheter. Peritoneal dialysis uses a peritoneal catheter. Access has its own identity, location, insertion/creation date, complications and maintenance state.

The access should therefore travel across Emergency Care, Surgery, Infectious Disease and community services. Dialysis patient ≠ access healthy.

4. Fluid removal is not simply “take off as much as possible”

Excess fluid can cause oedema, hypertension and pulmonary congestion. Removing fluid too aggressively can produce hypotension, cramps, organ under-perfusion and poor treatment tolerance. Dialysis therefore requires repeated comparison of intake, residual urine, weight trend, symptoms, blood pressure and clinical examination.

For eduKateAI: more ultrafiltration ≠ better dialysis. The meaningful state is whether fluid balance is safe and sustainable.

5. Dialysis adequacy is more than one number

Measures of solute clearance can help assess treatment delivery, but adequacy also includes volume control, symptom burden, nutrition, biochemical control, residual kidney function, access performance and whether the person can sustain the treatment plan.

The return receipt should therefore not collapse to a single clearance metric.

6. Electrolyte and acid–base states can change between treatments

Potassium, bicarbonate, sodium and other solutes can accumulate or shift between dialysis sessions. Their significance depends on timing, diet, medicines, residual kidney function, treatment delivery and the patient’s clinical state.

Renal Medicine owns interpretation of the internal environment; this node owns how the dialysis prescription and schedule alter that state over time.

7. Dialysis can change medicine exposure

Some medicines are removed by dialysis while others are not. Timing, protein binding, volume of distribution and dialysis modality can affect exposure. Pharmacy owns medicine identity and safe administration; Therapeutic Drug Monitoring may become relevant for selected medicines.

For eduKateAI, kidney failure dose adjustment ≠ dialysis dose adjustment automatically.

8. Infection risk follows access and setting

Dialysis access can become infected. Peritoneal dialysis can be complicated by peritonitis. Haemodialysis catheters have different infection risks from mature fistulas. The infection therefore needs both an Infectious Disease route and an access-specific dialysis route.

Antimicrobial Stewardship & Infection Prevention owns prevention and responsible treatment; Dialysis owns the device/access state that created or modifies the risk.

9. Home dialysis changes the receiver

Peritoneal dialysis shifts substantial treatment work into the home: supplies, storage, aseptic technique, machine or manual exchanges, troubleshooting and caregiver/patient capability become part of the clinical state. MOH’s 2026 PD-preferred strategy explicitly recognises practical barriers such as equipment concerns and home storage and is supporting home PD through the National PD Home Support Programme.

For eduKateAI, home treatment must preserve patient/caregiver capability, equipment state, supply continuity, home constraints and escalation route.

10. Community dialysis is also an access-and-capacity system

Singapore’s MOH currently subsidises both community haemodialysis and peritoneal dialysis, with enhanced community dialysis subsidy frameworks effective from 1 July 2026. The practical route therefore includes transport, centre availability, funding and treatment frequency—not only physiology.

This is where HealthOS enters: dialysis can be medically appropriate yet fail if the patient cannot reliably reach or sustain the treatment.

11. Dialysis does not erase transplantation or conservative care

A person receiving dialysis may later enter a transplant pathway, remain on dialysis long term, or choose a conservative kidney-management pathway depending on health, eligibility, goals and circumstances. Dialysis should not be represented as the only possible endpoint of kidney failure.

Transplantation Medicine owns the transplant trajectory; Palliative/Supportive Care can run in parallel where goals and serious illness make symptom-focused care central.

12. The dialysis receipt is longitudinal

One successful session does not establish stable long-term treatment. Access function, volume control, biochemical state, infection, cardiovascular tolerance, treatment adherence, nutrition and quality of life all change over time.

The node therefore behaves like a recurring runtime: prescription → treatment → receipt → adjust → repeat.

Characteristic failure modes

• Dialysis = disease error: kidney failure and kidney-replacement treatment collapse together.
• HD = PD error: modality-specific access and complications disappear.
• Access invisible error: catheter/fistula/peritoneal access identity is lost across handoffs.
• More fluid removal = better error: treatment aggressiveness replaces physiological tolerance.
• One-number adequacy error: clearance metric substitutes for whole-patient treatment success.
• Home = hospital error: caregiver, equipment, storage and supply constraints disappear.
• Session-success endpoint: one completed treatment is mistaken for stable longitudinal control.

The eduKateAI routing contract

• Canonical public owner: Dialysis & Kidney Replacement Therapy Web.
• Input state: patient requiring or already receiving haemodialysis/peritoneal dialysis.
• Primary job: preserve modality, access, prescription, treatment delivery, adequacy, complications and community/home continuity as a persistent state.
• Do not collapse: kidney failure ≠ dialysis; HD ≠ PD; access present ≠ access functioning; session complete ≠ longitudinally stable.
• Handoffs: Renal Medicine, Vascular/Interventional services, Surgery, Infectious Disease, Antimicrobial Stewardship, Pharmacy, Clinical Nutrition, Cardiovascular Medicine, Transplantation, Palliative Care and HealthOS/community services.
• Return receipt: treatment delivered/missed, access functioning/not functioning, volume and solute goals met/not met, complications present/absent, next session/home plan accepted.

Authoritative routes

• Singapore MOH — Dialysis services
• Singapore MOH — 2026 PD-preferred strategy
• Singapore MOH — Community dialysis subsidies, updated 1 July 2026

Educational boundary: this article explains dialysis and kidney-replacement information architecture. It does not choose dialysis modality, prescribe a dialysis session, set fluid-removal targets, interpret dialysis adequacy or manage access complications for an individual patient.